SI2743348T1 - Novo protitelo proti-humanemu ngf - Google Patents

Novo protitelo proti-humanemu ngf Download PDF

Info

Publication number
SI2743348T1
SI2743348T1 SI201231222T SI201231222T SI2743348T1 SI 2743348 T1 SI2743348 T1 SI 2743348T1 SI 201231222 T SI201231222 T SI 201231222T SI 201231222 T SI201231222 T SI 201231222T SI 2743348 T1 SI2743348 T1 SI 2743348T1
Authority
SI
Slovenia
Prior art keywords
fab
fragment
human ngf
antibody
polynucleotide
Prior art date
Application number
SI201231222T
Other languages
English (en)
Inventor
Masazumi Kamohara
Hirotsugu Tanaka
Yukari Koya
Jun Takasaki
Atsuo Yonezawa
Eiji Yoshimi
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of SI2743348T1 publication Critical patent/SI2743348T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (6)

  1. NOVO PROTITELO PROTI-HUMANEMU NGF PATENTNI ZAHTEVKI
    1. Fab' fragment protitelesa proti humanemu NGF, ki obsega: fragment težke verige, ki sestoji iz aminokislinske sekvence, prikazane s SEQ ID NO:10, SEQ ID NO:14 ali SEQ ID NO:16; in lahko verigo, ki sestoji iz aminokislinske sekvence, prikazane s SEQ ID NO: 12, kjer je Fab 'fragment konjugiran s polietilenglikolom.
  2. 2. Fab' fragment po zahtevku 1, ki obsega: fragment težke verige, ki sestoji iz aminokislinske sekvence, prikazane s SEQ ID NO:14; in lahka veriga, ki sestoji iz aminokislinske sekvence, prikazane s SEQ ID NO: 12, kjer je Fab 'fragment konjugiran s polietilenglikolom.
  3. 3. Metoda za pripravo Fab' fragmenta protitelesa proti-humanemu NGF, ki obsega izražanje Fab' fragmenta protitelesa proti-humanemu NGF z gojenjem gostiteljske celice, izbrane iz skupine, ki jo sestavljajo (a) in (b), (a) gostiteljsko celico, transformirano z ekspresijskim vektorjem, ki obsega polinukleotid, ki obsega sekvenco, ki kodira fragment težke verige Fab' fragmenta po zahtevku 1 in polinukleotid, ki obsega sekvenco, ki kodira lahko verigo Fab' fragmenta po zahtevku 1; in (b) gostiteljsko celico, transformirano z ekspresijskim vektorjem, ki obsega polinukleotid, ki obsega sekvenco, ki kodira fragment težke verige Fab' fragmenta po zahtevku 1 in z ekspresijskim vektorjem ki obsega polinukleotid, ki obsega sekvenco, ki kodira lahko verigo Fab' fragmenta v skladu po zahtevku 1, in konjugiranje Fab' fragmenta protitelesa proti-humanemu NGF s polietilen glikolom.
  4. 4. Metoda za pripravo Fab' fragmenta protitelesa proti-humanemu NGF, ki obsega izražanje Fab' fragmenta protitelesa proti-humanemu NGF z gojenjem gostiteljske celice, izbrane iz skupine, ki jo sestavljajo (a) in (b), (a) gostiteljsko celico, transformirano z ekspresijskim vektorjem, ki obsega polinukleotid, ki obsega sekvenco, ki kodira fragment težke verige Fab' fragmenta po zahtevku 2 in polinukleotid, ki obsega sekvenco, ki kodira lahko verigo Fab' fragmenta po zahtevku 2; in (b) gostiteljsko celico, transformirano z ekspresijskim vektorjem, ki obsega polinukleotid, ki obsega sekvenco, ki kodira fragment težke verige Fab' fragmenta po zahtevku 2 in z ekspresijskim vektorjem ki obsega polinukleotid, ki obsega sekvenco, ki kodira lahko verigo Fab' fragmenta v skladu po zahtevku 2, in konjugiranje Fab' fragmenta protitelesa proti-humanemu NGF s polietilen glikolom.
  5. 5. Fab' fragment protitelesa proti humanemu NGF proizveden po postopku po zahtevku 3.
  6. 6. Fab' fragment protitelesa proti humanemu NGF proizveden po postopku po zahtevku 4.
SI201231222T 2011-08-11 2012-08-10 Novo protitelo proti-humanemu ngf SI2743348T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011176209 2011-08-11
JP2011269215 2011-12-08
PCT/JP2012/070433 WO2013022083A1 (ja) 2011-08-11 2012-08-10 新規抗ヒトｎｇｆ抗体
EP12821758.5A EP2743348B1 (en) 2011-08-11 2012-08-10 Novel anti-human ngf antibody

Publications (1)

Publication Number Publication Date
SI2743348T1 true SI2743348T1 (sl) 2018-04-30

Family

ID=47668585

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231222T SI2743348T1 (sl) 2011-08-11 2012-08-10 Novo protitelo proti-humanemu ngf

Country Status (28)

Country Link
US (2) US8986952B2 (sl)
EP (1) EP2743348B1 (sl)
JP (1) JP5376095B2 (sl)
KR (1) KR101999867B1 (sl)
CN (1) CN103748222B (sl)
AR (1) AR087506A1 (sl)
AU (1) AU2012293161B2 (sl)
BR (1) BR112014002576B1 (sl)
CA (1) CA2841181C (sl)
CY (1) CY1119914T1 (sl)
DK (1) DK2743348T3 (sl)
EA (1) EA024292B1 (sl)
ES (1) ES2663968T3 (sl)
HR (1) HRP20180155T1 (sl)
HU (1) HUE036079T2 (sl)
IL (1) IL230797A (sl)
IN (1) IN2014CN00614A (sl)
LT (1) LT2743348T (sl)
ME (1) ME02944B (sl)
MX (1) MX351273B (sl)
NO (1) NO2743348T3 (sl)
PL (1) PL2743348T3 (sl)
PT (1) PT2743348T (sl)
RS (1) RS56876B1 (sl)
SI (1) SI2743348T1 (sl)
TW (1) TWI554519B (sl)
WO (1) WO2013022083A1 (sl)
ZA (1) ZA201400741B (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US8728473B2 (en) 2010-12-01 2014-05-20 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
MY184164A (en) * 2015-05-22 2021-03-24 Astellas Pharma Inc Novel anti-human ngf antibody fab fragment
US20200299371A1 (en) * 2016-03-25 2020-09-24 Astellas Pharma Inc. Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
WO2019221097A1 (ja) 2018-05-15 2019-11-21 アステラス製薬株式会社 抗ヒトｎｇｆ抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0690132B1 (en) * 1993-03-11 2003-12-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-hiv monoclonal antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA03010911A (es) 2001-05-30 2004-02-17 Genentech Inc Anticuerpos contra ngf para el tratamiento de varios desordenes.
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP1575517B1 (en) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
JP4489077B2 (ja) 2003-07-15 2010-06-23 アムジェン インコーポレイテッド 選択的ｎｇｆ経路インヒビターとしてのヒト抗ｎｇｆ中和抗体
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
NZ556157A (en) 2005-01-24 2009-09-25 Elan Pharma Int Ltd Specific binding members for NGF
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
KR101709488B1 (ko) * 2007-08-10 2017-02-24 리제너론 파아마슈티컬스, 인크. 인간 신경성장인자에 대한 고친화성 인간 항체
BRPI0818201B8 (pt) 2007-10-24 2021-05-25 Astellas Pharma Inc composto de azolcarboxamida ou sal do mesmo e uso do mesmo para o tratamento de frequência urinária, urgência urinária, incontinência urinária e dores do trato urinário inferior associadas com várias doenças do trato urinário inferior, e várias doenças acompanhadas de dor
AR076650A1 (es) 2009-05-04 2011-06-29 Pangenetics 110 B V Anticuerpos contra el factor de crecimiento nervioso (ngf) con una estabilidad in vivo mejorada

Also Published As

Publication number Publication date
IN2014CN00614A (sl) 2015-04-03
US20140155582A1 (en) 2014-06-05
MX2014001627A (es) 2014-05-28
PL2743348T3 (pl) 2018-04-30
CN103748222B (zh) 2015-07-22
KR20140047116A (ko) 2014-04-21
EP2743348A1 (en) 2014-06-18
CA2841181A1 (en) 2013-02-14
EA201490433A1 (ru) 2014-05-30
HUE036079T2 (hu) 2018-06-28
BR112014002576B1 (pt) 2022-08-23
AU2012293161A1 (en) 2014-02-06
JPWO2013022083A1 (ja) 2015-03-05
CN103748222A (zh) 2014-04-23
TWI554519B (zh) 2016-10-21
CA2841181C (en) 2022-01-25
JP5376095B2 (ja) 2013-12-25
ES2663968T3 (es) 2018-04-17
PT2743348T (pt) 2018-02-23
KR101999867B1 (ko) 2019-07-12
TW201319086A (zh) 2013-05-16
NO2743348T3 (sl) 2018-06-09
WO2013022083A1 (ja) 2013-02-14
BR112014002576A2 (pt) 2021-01-12
EP2743348B1 (en) 2018-01-10
ME02944B (me) 2018-04-20
ZA201400741B (en) 2014-11-26
EA024292B1 (ru) 2016-09-30
AU2012293161B2 (en) 2017-04-27
LT2743348T (lt) 2018-05-10
DK2743348T3 (en) 2018-02-26
IL230797A0 (en) 2014-03-31
US20150218265A1 (en) 2015-08-06
US8986952B2 (en) 2015-03-24
MX351273B (es) 2017-10-06
IL230797A (en) 2017-06-29
HRP20180155T1 (hr) 2018-03-23
EP2743348A4 (en) 2015-04-29
AR087506A1 (es) 2014-03-26
CY1119914T1 (el) 2018-06-27
RS56876B1 (sr) 2018-04-30

Similar Documents

Publication Publication Date Title
SI2743348T1 (sl) Novo protitelo proti-humanemu ngf
HRP20201505T1 (hr) Široko neutralizirajuća anti-hiv protutijela
NZ611468A (en) Humanized antibodies to liv-1 and use of same to treat cancer
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
NZ706377A (en) Il-6 antagonists and uses thereof
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
BR112014002613A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método
EA035160B9 (ru) Антитела к st2 и их применение
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201490288A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
BR112012021327B8 (pt) anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo.
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2013141956A (ru) Антитело против ксф-1r
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
AU2011262758A8 (en) Anti-tim-3 antibody
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
WO2013041845A3 (en) Animals, repertoires & methods for the production of human antibodies
NZ714516A (en) Human antibodies to clostridium difficile toxins
RU2013135175A (ru) Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом
PH12019501104A1 (en) Novel anti-human muc1 antibody fab fragment
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)